Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xingnao Dripping Pills
- Development stage
- Phase 3
- Lead developer
- Tasly Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Xingnao Dripping Pills is a Traditional Chinese Medicine (TCM) product developed by Tianjin Tasly Pharmaceutical Co., Ltd., specifically indicated for the treatment of vascular dementia and cognitive impairment. The formulation is an oral dripping pill version of the traditional Xingnao Jing formula, optimized for enhanced stability, bioavailability, and rapid absorption. It is composed of four primary active ingredients: Borneolum Syntheticum (borneol), Moschus (artificial musk), Gardenia jasminoides, and Radix Curcumae. The therapeutic mechanism of Xingnao Dripping Pills involves a multi-target approach, including the reduction of neuroinflammation by inhibiting pro-inflammatory cytokines, the improvement of cerebral microcirculation, and neuroprotection against ischemic damage. Additionally, it has been shown to modulate neurotransmitter levels, particularly by increasing cholinergic activity in the brain, which is critical for cognitive function. In China, it is a recognized pharmaceutical intervention for patients suffering from vascular-related cognitive decline.
- Brand names
- Xingnao Dripping Pills
- Other names
- Xingnao Diwan
02
Targets
AcetylcholinesteraseIL1B (Interleukin-1 beta)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on Xingnao Dripping Pills.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xingnao Dripping Pills.